Thyroid Neoplasm
Conditions
Keywords
Depakote, Poorly Differentiated Thyroid Cancer, RAI Uptake, Thyrogen
Brief summary
Background: * Patients who have advanced thyroid cancer have a low long-term survival rate. These types of thyroid cancer do not respond well to conventional surgery or radiation, or to specific thyroid cancer treatments such as radioactive iodine treatment and thyroid hormone for thyroid stimulating hormone (TSH) suppression. * Valproic acid has long been approved as an anticonvulsant to treat seizures in patients with epilepsy. It has also been used to treat bipolar disorder. Recent studies have shown that valproic acid has promising effects in thyroid cancer treatment because it may help destroy cancer cells and help conventional treatments be more effective. However, valproic acid is not approved for thyroid cancer and is therefore an investigational drug. Objectives: * To determine whether valproic acid can inhibit tumor growth or induce tumor cell death. * To determine whether valproic acid can make tumor cells increase their uptake of radioiodine. Eligibility: \- Individuals at least 18 years of age who have advanced-stage thyroid cancer that is either unresponsive to conventional treatments or fails to absorb radioiodine. Design: * Eligible participants will continue on the standard thyroid hormone suppression therapy and begin receiving valproic acid for a total of 10 weeks. Participants will keep a study diary to record doses and side effects, and will have regular clinic visits to provide blood samples and receive additional valproic acid. * After 10 weeks, participants will have a Thyrogen scan to measure radioiodine uptake after valproic acid therapy. Tumor biopsies and blood samples will be taken at this time. * If there is increased radioiodine uptake on the scan, participants will have additional radioiodine therapy. * If there is no increased uptake on the scan, participants will continue on valproic acid for 7 more weeks. After 16 total weeks of treatment, additional blood samples and scans will be taken. Participants may continue to take valproic acid if the thyroid cancer appears to be responding to the treatment. * Follow-up visits will be scheduled at 3, 6, 9 (for patients continuing on valproic acid only), and 12 months.
Detailed description
Background: Patients who have advanced differentiated thyroid cancers (Stage IV) have a five-year survival of only 25%. Clinically this results in more aggressive growth, metastasis, decreased or loss of iodine uptake in the tumor, and tumors that may be refractory to conventional treatment: surgical resection, radioactive iodine treatment and thyroid hormone for Thyroid Stimulating Hormone (TSH) suppression. In thyroid cancer, valproic acid, at clinically achievable concentrations, has an antiproliferative and differentiating effect. We hypothesize that valproic acid may inhibit proliferation and induce differentiation in thyroid cancer cells so that 131-I may detect residual disease and be more effective for radioiodine ablation of thyroid cancer cells of follicular cell origin. Objectives: The primary goal of this study is to determine if valproic acid will have an antineoplastic and differentiation effect in patients with advanced and or metastatic thyroid cancer of follicular cell origin. Eligibility: Unresectable advanced and/or poorly differentiated thyroid cancers of follicular cell origin (excluding anaplastic and medullary thyroid cancer) that have no uptake (less than 1%) on radioiodine scan or are unresponsive to radioiodine therapy. Elevated serum thyroglobulin (Tg) level (greater than 100ng/ml on thyroid hormone; greater than 10ng/ml off thyroid hormone). Design: This will be an open label phase II study to assess the efficacy of valproic acid therapy as an antiproliferative and differentiation agent in patients with incurable differentiated thyroid cancer (unresponsive and/or radioiodine negative and unresectable). Oral valproic acid will be administered to reach a therapeutic serum level (50 to 100 microgram/ml). The number of patients to be enrolled is 25 with an interim analysis of response once 13 patients are evaluable for response. It is anticipated that five patients may be enrolled per year.
Interventions
DRUGValproic Acid
Week 1: (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: 1. Advanced/poorly differentiated thyroid cancers of follicular cell origin that have no uptake (less than 1%) on radioiodine scan or are unresponsive to radioiodine therapy. Unresponsiveness to radioiodine therapy is defined as a patient s thyroglobulin not falling to less than 2ng/ml within 6 months after previous radioiodine ablative treatment. 2. Extensive (invasive) loco-regional tumor mass and/or metastatic spread, rendering patient inoperable. 3. Thyroglobulin (Tg) levels greater than or equal to 100 ng/ml in the absence of Tg antibodies. Patients who are Tg-antibody (Tg-Ab) positive may be included despite a lower Tg level if they have detectable disease on cross sectional imaging. (The presence of Tg-Ab may lead to falsely low Tg levels and therefore render the Tg a less sensitive marker of disease. However, Tg-Ab has been shown to also act as a tumor marker, and will be used as an endpoint for the study in patients who are Tg-Ab positive.). 4. Within 18 months of enrollment, patients must have had an radioactive iodine (RAI) scan, showing no or therapeutically insignificant RAI uptake (less than or equal to 1%). 5. Initial therapy must have included total/near-total thyroidectomy and RAI ablation therapy. 6. Patients must have had no chemotherapy, radiotherapy, or biologic therapy for their malignancy in the month prior to treatment and must have recovered from all side effects of therapeutic and diagnostic interventions. 7. Greater than or equal to 18 years of age. 8. Must be able to understand and sign the Informed Consent Document. 9. Clinical performance status of Eastern Oncology Cooperative Group (ECOG) less than or equal to 1. 10. Life expectancy of greater than three months. 11. Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) within 72 hours prior to study entry and must be willing to practice effective birth control to prevent pregnancy while receiving treatment and for three months after treatment is discontinued. All males of child fathering potential must also be willing to practice effective birth control. 12. Laboratory results must be within the following parameters before entry: * Absolute Neutrophil Count greater than 750 cells/mm(3) * Hemoglobin greater than 8.0 gm/dl * Platelet count greater than 75000/mm(3) * Creatinine less tha 1.5 times upper limit of normal (ULN) * Total protein greater than 6.4. * Total bilirubin should be less than 1.5 times ULN. * Aspartate aminotransferase (AST) serum glutamic oxaloacetic (SGOT), alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) less than 1.5 times ULN. * Amylase less than 1.5 times ULN * Ammonia less than 1.5 times ULN
Exclusion criteria
1. Allergy to valproic acid. 2. Current coexisting malignancy other than basal cell carcinoma. 3. Women of child-bearing potential who are pregnant or breastfeeding. Valproic acid is a known teratogen, causing primary neural tube defects, facial abnormalities, and skeletal malformation; therefore pregnant women will be excluded. Additionally, patients that become pregnant while on study protocol will be discontinued immediately. 4. Active systemic infections, coagulation disorders or other major medical illnesses. 5. Patients taking tolbutamide, warfarin, zidovudine, benzodiazepines, clonazepam, diazepam. 6. Seizure disorder.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Entry to study and after 10 weeks of treatment for Phase 1, and 10 weeks of treatment to 16 weeks of treatment for phase 2. | Complete response (CR) is increased Rai uptake on post- valproic acid therapy at week 10, AND a decrease in Tg level to less than 2 ng/ml (or a decrease in Tg-Ab level to less than 2.0 IU/ml) at 10 weeks AND disappearance of all lesions at 16 weeks. Partial response (PR) is increased Rai uptake on post-valproic scan at week 10, OR a decreased Tg level (or a decrease in Tg Ab (Tg antibody) level by more than 20%) at 10 weeks AND 30% decrease in target lesion at 16 weeks. Stable disease (SD) is no change in RAI uptake AND Tg levels (or TG-Ab level) AND no significant change of lesions at 16 weeks. Progressive disease (PD) is tumor mass increases OR Tg levels (or Tg-Ab levels) increases over 10 weeks OR at least 20% increase in target lesion at 16 weeks. |
| Number of Participants With Adverse Events | Date treatment consent signed to date off study, approximately 41 months and 11 days | Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best Overall Response | Week 16 | Best overall response was assessed by radioiodine uptake. Complete response (CR) is increased Rai (radioiodine) uptake on post- valproic acid therapy at week 10, AND a decrease in Tg (thyroglobulin ) level to less than 2 ng/ml (or a decrease in Tg-Ab (thyroglobulin antibodies) level to less than 2.0 IU/ml) at 10 weeks AND disappearance of all lesions at 16 weeks. Partial response (PR) is increased Rai uptake on post-valproic scan at week 10, OR a decreased Tg level (or a decrease in Tg Ab (Tg antibody) level by more than 20%) at 10 weeks AND 30% decrease in target lesion at 16 weeks. Stable disease (SD) is no change in RAI uptake AND Tg levels (or TG-Ab level) AND no significant change of lesions at 16 weeks. Progressive disease (PD) is tumor mass increases OR Tg levels (or Tg-Ab levels) increases over 10 weeks OR at least 20% increase in target lesion at 16 weeks. |
| NIS (Na/I-symporter) Expression | Entry to study and after 10 weeks of treatment | NIS (Na/I-symporter) Expression is assessed by quantitative reverse transcription (RT) polymerase chain reaction (PCR) and immunohistochemistry (IHC). NIS mRNA expression was measured by quantitative RT PCR from biopsy samples. |
Countries
United States
Participant flow
Pre-assignment details
Five and eight participants were enrolled from University of California San Francisco (UCSF) and the National Institutes of Health (NIH), respectively.
Participants by arm
| Arm | Count |
|---|---|
| All Participants (Phase 1 and Phase 2 Schedule 2) A- Phase 1 Radioiodine-Resistant Drug: Valproic Acid Week 1 - 10 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
B2 - Phase 2 Schedule 2 Drug: Valproic Acid Week 11 - 52 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Weeks 17-52: Patients who show a response by RECIST criteria or have a decreased thyroglobulin level from Day 1 of the treatment (registered as a partial response to the treatment) will continue on valproic acid at their current dose for a total of 52 weeks. | 13 |
| Total | 13 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| First Intervention Week 1-10 | Adverse Event | 1 | 0 | 0 |
| First Intervention Week 1-10 | Disease progression | 1 | 0 | 0 |
| First Intervention Week 1-10 | Non-compliance | 1 | 0 | 0 |
| Third Intervention Week 11-52 | Disease Progression | 0 | 0 | 6 |
| Third Intervention Week 11-52 | Other | 0 | 0 | 2 |
Baseline characteristics
| Characteristic | All Participants (Phase 1 and Phase 2 Schedule 2) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 4 Participants |
| Age, Categorical Between 18 and 65 years | 9 Participants |
| Age, Continuous | 61.08 years STANDARD_DEVIATION 7.63 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 11 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 9 Participants |
| Region of Enrollment United States | 13 Participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 13 |
| other Total, other adverse events | 8 / 13 |
| serious Total, serious adverse events | 2 / 13 |
Outcome results
Primary
Number of Participants With Adverse Events
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.
Time frame: Date treatment consent signed to date off study, approximately 41 months and 11 days
Population: Adverse events are not reported per Arm. All adverse events were reported to include phases 1 and 2 since it is analyzed throughout the whole study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | Number of Participants With Adverse Events | 8 Participants |
Primary
RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment
Complete response (CR) is increased Rai uptake on post- valproic acid therapy at week 10, AND a decrease in Tg level to less than 2 ng/ml (or a decrease in Tg-Ab level to less than 2.0 IU/ml) at 10 weeks AND disappearance of all lesions at 16 weeks. Partial response (PR) is increased Rai uptake on post-valproic scan at week 10, OR a decreased Tg level (or a decrease in Tg Ab (Tg antibody) level by more than 20%) at 10 weeks AND 30% decrease in target lesion at 16 weeks. Stable disease (SD) is no change in RAI uptake AND Tg levels (or TG-Ab level) AND no significant change of lesions at 16 weeks. Progressive disease (PD) is tumor mass increases OR Tg levels (or Tg-Ab levels) increases over 10 weeks OR at least 20% increase in target lesion at 16 weeks.
Time frame: Entry to study and after 10 weeks of treatment for Phase 1, and 10 weeks of treatment to 16 weeks of treatment for phase 2.
Population: 13 participants were enrolled in phase 1 and 8/13 (5 from University of California San Francisco (UCSF) moved on from phase 1 to the phase 2 schedule 2 portion. However, Tg data from UCSF is unavailable for 5 of the participant, thus only 3 were analyzed in the phase 2 portion.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 99 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 707 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 661 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 362 ng/ml | 0 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 289 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 183 ng/ml | 0 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 154 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 101 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - >900 ng/ml | 6 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 15.7 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg start - 142 IU/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg start - 220 IU/ml | 0 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg start - <20 IU/ml | 7 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - >900 ng/ml | 4 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 749 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 702 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 630 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 480 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 362 ng/ml | 0 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 204 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 184 ng/ml | 0 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 183 ng/ml | 0 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 128 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 61 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 10.8 ng/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - none | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg end - 338 IU/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | anti Tg end - 220 IU/ml | 0 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg end - 83 IU/ml | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg end - 80 IU/ml | 0 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | anti Tg end - <20 IU/ml | 5 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg end - none | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | RAI uptake pre-treatment - none | 13 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | RAI uptake post treatment - none | 10 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - none | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - >900 ng/ml | 1 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 480 ng/ml | 1 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 707 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | RAI uptake post treatment - none | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 661 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 362 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 362 ng/ml | 1 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg end - 338 IU/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 289 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 204 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 183 ng/ml | 1 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | anti Tg end - <20 IU/ml | 2 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 154 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 184 ng/ml | 1 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 101 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | anti Tg end - 220 IU/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 99 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 183 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg start - 15.7 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | RAI uptake pre-treatment - none | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg start - 142 IU/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 128 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg start - 220 IU/ml | 1 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg end - 83 IU/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg start - <20 IU/ml | 2 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 61 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - >900 ng/ml | 1 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg end - none | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 749 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 10.8 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 702 ng/ml | 0 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | antiTg end - 80 IU/ml | 1 Participants |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment | Tg end - 630 ng/ml | 0 Participants |
Secondary
Best Overall Response
Best overall response was assessed by radioiodine uptake. Complete response (CR) is increased Rai (radioiodine) uptake on post- valproic acid therapy at week 10, AND a decrease in Tg (thyroglobulin ) level to less than 2 ng/ml (or a decrease in Tg-Ab (thyroglobulin antibodies) level to less than 2.0 IU/ml) at 10 weeks AND disappearance of all lesions at 16 weeks. Partial response (PR) is increased Rai uptake on post-valproic scan at week 10, OR a decreased Tg level (or a decrease in Tg Ab (Tg antibody) level by more than 20%) at 10 weeks AND 30% decrease in target lesion at 16 weeks. Stable disease (SD) is no change in RAI uptake AND Tg levels (or TG-Ab level) AND no significant change of lesions at 16 weeks. Progressive disease (PD) is tumor mass increases OR Tg levels (or Tg-Ab levels) increases over 10 weeks OR at least 20% increase in target lesion at 16 weeks.
Time frame: Week 16
Population: Best overall response was not assessed for the phase 1 portion.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | Best Overall Response | Unknown | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | Best Overall Response | Complete Response (CR) | 0 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | Best Overall Response | Partial Response (PR) | 0 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | Best Overall Response | Stable Disease (SD) | 1 Participants |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | Best Overall Response | Progressive Disease (PD) | 6 Participants |
Secondary
NIS (Na/I-symporter) Expression
NIS (Na/I-symporter) Expression is assessed by quantitative reverse transcription (RT) polymerase chain reaction (PCR) and immunohistochemistry (IHC). NIS mRNA expression was measured by quantitative RT PCR from biopsy samples.
Time frame: Entry to study and after 10 weeks of treatment
Population: There is no standard of error to report. The acronym GAPDH expanded is glyceraldehyde 3-phosphate dehydrogenase. Only 1 participant was analyzed because biopsies were not performed in 12 subjects.
| Arm | Measure | Group | Value (MEDIAN) | Dispersion |
|---|---|---|---|---|
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | NIS (Na/I-symporter) Expression | Pre-treatment NIS expression (relative to GAPDH) | 21 percent expression | Standard Error 0 |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | NIS (Na/I-symporter) Expression | Post-treatment NIS expression (relative to GAPDH) | 25 percent expression | Standard Error 0 |